News & Updates

In the post hoc analysis of the AURORA 1 and 2 trials, the novel calcineurin inhibitor voclosporin was effective in achieving complete renal response (CRR)* in individuals with severe lupus nephritis** (LN).

Treatment with maralixibat significantly reduced the severity of pruritus in children with progressive familial intrahepatic cholestasis (PFIC) in the MARCH-PFIC* study presented at The Liver Meeting 2022.

A recent study in Ghana has shown significant improvements of participants’ knowledge in all aspects of cancer among community pharmacists compared to the results of the preassessment study.

Treatment with odevixibat, a potent, selective IBAT* inhibitor, significantly improved pruritus and reduced serum bile acid levels in children with Alagille syndrome (ALGS), according to the ASSERT** trial presented at The Liver Meeting 2022.

Use of antipsychotics, particularly long-acting injectables, results in nearly 30‒50-percent reduced risk of work disability among individuals with first-episode nonaffective psychosis compared with nonuse, a study has shown. This benefit persists beyond 5 years after first diagnosis.

Several barriers and facilitators indicate the need to create work environments where safety is a priority for the handling of antineoplastic drugs, suggests a Canada study.